FluoroPharma Medical (FluoroPharma Medical) Total Current Assets : $0.05 Mil (As of Dec. 2016)

View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. FluoroPharma Medical's total current assets for the quarter that ended in Dec. 2016 was $0.05 Mil.

FluoroPharma Medical Total Current Assets Historical Data

The historical data trend for FluoroPharma Medical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Total Current Assets Chart

FluoroPharma Medical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Current Assets

Get a 7-Day Free Trial

1.38

1.83

0.45

0.51

0.05

FluoroPharma Medical Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16
Total Current Assets	Get a 7-Day Free Trial															0.51	0.14	0.46	0.09	0.05

FluoroPharma Medical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

FluoroPharma Medical's Total Current Assets for the fiscal year that ended in Dec. 2016 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.025	+	0	+	0	+	0.023
	=	0.05

FluoroPharma Medical's Total Current Assets for the quarter that ended in Dec. 2016 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.025	+	0	+	0	+	0.023
	=	0.05

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

FluoroPharma Medical (OTCPK:FPMI) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

FluoroPharma Medical's Liquidation Value for the quarter that ended in Dec. 2016 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.025	-	10.514	+	0.75 * 0	+	0.5 * 0
=	-10.49

FluoroPharma Medical Total Current Assets Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

FluoroPharma Medical (FluoroPharma Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042

Website

http://www.fluoropharma.com

FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.

Executives

Johan M. Spoor

director, officer: CEO, PRESIDENT, CHAIRMAN

500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus

FPMI Restructures CardioPET License With Massachusetts General Hospital

By Marketwired Marketwired • 09-27-2018